tradingkey.logo

Illumina Inc

ILMN
View Detailed Chart

100.920USD

+5.800+6.10%
Close 09/15, 16:00ETQuotes delayed by 15 min
15.54BMarket Cap
12.35P/E TTM

Illumina Inc

100.920

+5.800+6.10%
Intraday
1m
30m
1h
D
W
M
D

Today

+6.10%

5 Days

+2.79%

1 Month

+0.81%

6 Months

+17.90%

Year to Date

-24.48%

1 Year

-21.88%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-15

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
61 / 207
Overall Ranking
195 / 4724
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 24 analysts
Hold
Current Rating
112.300
Target Price
+18.06%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Overvalued
The company’s latest PE is 12.74, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 167.87M shares, decreasing 9.74% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 15.08M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.31.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Ticker SymbolILMN
CompanyIllumina Inc
CEOMr. Jacob Thaysen, Ph.D.
Websitehttps://www.illumina.com
KeyAI